Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019

Latest 10-K

View 10-K

Stock Information

Cardax, Inc.

OTCQB: CDXI

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn® primarily through wholesale and e-commerce channels.

Contact Information

Investor Relations
Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com

Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598